National Comprehensive Cancer Network

About NCCN

2014 NCCN Fellows Recognition Program

On March 12, 2014, 60 fellows attended the 2014 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care™ as part of the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ in Hollywood, Florida.

The half-day meeting commenced with opening remarks from Joan S. McClure, MS, Senior Vice President, Clinical Information and Publications, NCCN, followed by a presentation from Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, titled, What’s New in the Management of Kidney Cancer? During his presentation, Dr. Jonasch summarized major renal cell carcinoma (RCC) treatment modalities by stage, discussed the necessity of upfront nephrectomy versus systemic therapy in certain patient populations, and presented data on a number of treatment options for first- and second-line treatment of RCC. The next 10 years will see major changes in the treatment of RCC, said Dr. Jonasch.

Following Dr. Jonasch, Maria Arcila, MD, Memorial Sloan-Kettering Cancer Center, discussed the challenges in assessing and using biomarkers in oncology care. Dr. Arcila noted that, although there have been notable achievements in biomarker research, only a few biomarkers are used routinely in oncology care; the challenges in the way of more widespread use include, but are not limited to the availability of tools and resources for testing, inclusion of biomarkers testing in treatment guidelines and standards, and widespread education and communication, as well as ethical, social, and political barriers. Biomarkers will be instrumental in redefining cancer as a treatable, or even curable, disease, she said.

During her presentation, Lori J. Goldstein, MD, Fox Chase Cancer Center, discussed the application of appropriate clinical tools to estimate risk of relapse or death in patients with breast cancer and the benefits of systemic adjuvant treatment, as well as the selection of optimal adjuvant treatment plans for patients, based on the extent the tumor, as well as hormone receptor and HER2 status. She discussed the optimal duration of hormonal adjuvant therapy and emphasized that data support continuation of tamoxifen beyond 5 years. Dr. Goldstein also provided insight into the NCCN Guidelines panel’s consideration of the use of pertuzumab containing regimens in the neoadjuvant versus adjuvant setting.  

What is the Optimal Sequence of Systemic Therapy in Metastatic Colorectal Cancer?, presented by Tonios Bekaii-Saab, MD, The University of Ohio Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discussed the integration of the recent addition of new agents into the continuum of care for patients with metastatic colorectal cancer, options for first-, second-, and third-line treatment of unresectable metastatic colorectal cancer, and the choice of biomarkers in first-line treatment. Individualized care, he noted, includes molecular characterization and personalization of care, taking into consideration patient goals, preferences, comorbidities, and performance status.

The 2014 NCCN Fellows Recognition Program concluded as Michael B. Streiff, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, presented developments in the optimal management of venous thromboembolism (VTE) in cancer patients, including but not limited to the risk factors for VTE in cancer patients, VTE prophylaxis in ambulatory and hospitalized cancer patients, and a review of the role of new oral anticoagulants in the treatment of VTE in people with cancer.

NCCN plans to hold the next NCCN Fellows Recognition Program during the NCCN 20th Annual Conference in March 2015.